Eli Lilly announces Phase 3 ATTAIN-2 trial results for oral GLP-1 agonist orforglipron in obesity… EP News Bureau Aug 28, 2025 ATTAIN-2 met primary and key secondary endpoints, with weight loss, A1C reductions, and cardiometabolic improvements at 72 weeks
